Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech ...

Norway's sovereign wealth fund, the world's largest, said on Monday it will abstain from voting on new board members at ...

Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...

Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current ...

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

The starting dose of 0.25 mg will now cost Rs 2,712 per week, down from Rs 4,336 earlier, with the new prices effective ...

Novo Nordisk, the global healthcare leader in the treatment of chronic diseases such as diabetes and obesity, has announced ...

Norway’s sovereign wealth fund said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk’s extraordinary shareholders’ meeting on November 14.

The Novo Nordisk Foundation in Denmark, one of the world’s leading funders of pharmaceutical and biotechnology research, is investing €21.7 million to support emerging and rising Danish researchers in ...

Novo Nordisk stock rose 2.6% after withdrawing from a $10 billion bidding war for Metsera that investors viewed as too ...

As we found in our recent research, our brains also have powerful mechanisms for defending body weight – and can sort of ...

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.